103 related articles for article (PubMed ID: 8077983)
21. Antimicrobial susceptibility of Brucella melitensis isolates in Peru.
Maves RC; Castillo R; Guillen A; Espinosa B; Meza R; Espinoza N; Núñez G; Sánchez L; Chacaltana J; Cepeda D; González S; Hall ER
Antimicrob Agents Chemother; 2011 Mar; 55(3):1279-81. PubMed ID: 21199926
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
23. Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region.
Tanyel E; Coban AY; Koruk ST; Simsek H; Hepsert S; Cirit OS; Tulek N
Saudi Med J; 2007 Aug; 28(8):1239-42. PubMed ID: 17676210
[TBL] [Abstract][Full Text] [Related]
24. In vitro antimicrobial susceptibility of Brucella species.
Baykam N; Esener H; Ergönül O; Eren S; Celikbas AK; Dokuzoguz B
Int J Antimicrob Agents; 2004 Apr; 23(4):405-7. PubMed ID: 15081093
[TBL] [Abstract][Full Text] [Related]
25. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.
Liu ZG; Di DD; Wang M; Liu RH; Zhao HY; Piao DR; Zhao ZZ; Hao YQ; Du YN; Jiang H; Cui BY; Xia XZ
BMC Infect Dis; 2018 Jan; 18(1):43. PubMed ID: 29338693
[TBL] [Abstract][Full Text] [Related]
26. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
27. Biotypes and antimicrobial susceptibilities of Brucella isolates.
Bodur H; Balaban N; Aksaray S; Yetener V; Akinci E; Colpan A; Erbay A
Scand J Infect Dis; 2003; 35(5):337-8. PubMed ID: 12875523
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 - 2015.
Deshmukh A; Hagen F; Sharabasi OA; Abraham M; Wilson G; Doiphode S; Maslamani MA; Meis JF
BMC Microbiol; 2015 Jun; 15():121. PubMed ID: 26073177
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
30. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC.
Deguchi T; Yasuda M; Ishihara S; Takahashi Y; Okezaki E; Nagata O; Saito I; Kawada Y
J Antimicrob Chemother; 1997 Sep; 40(3):437-9. PubMed ID: 9338500
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
32. In vitro antimicrobial susceptibility of Brucella melitensis isolates from sheep in an area endemic for human brucellosis in Turkey.
Ilhan Z; Solmaz H; Ekin IH
J Vet Med Sci; 2013; 75(8):1035-40. PubMed ID: 23545462
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs.
Akova M; Gür D; Livermore DM; Kocagöz T; Akalin HE
Antimicrob Agents Chemother; 1999 May; 43(5):1298-300. PubMed ID: 10223958
[TBL] [Abstract][Full Text] [Related]
34. Comparative in-vitro activity of sparfloxacin against genital pathogens.
Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
[TBL] [Abstract][Full Text] [Related]
35. In vitro efficacy of several antimicrobial combinations against Brucella canis and Brucella melitensis strains isolated from dogs.
Mateu-de-Antonio EM; Martín M
Vet Microbiol; 1995 Jun; 45(1):1-10. PubMed ID: 7653024
[TBL] [Abstract][Full Text] [Related]
36. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis.
Valdezate S; Navarro A; Medina-Pascual MJ; Carrasco G; Saéz-Nieto JA
J Antimicrob Chemother; 2010 Jan; 65(1):51-3. PubMed ID: 19861338
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Dalhoff A; Petersen U; Endermann R
Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
[TBL] [Abstract][Full Text] [Related]
38. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
Child J; Andrews J; Boswell F; Brenwald N; Wise R
J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of
Shevtsov A; Syzdykov M; Kuznetsov A; Shustov A; Shevtsova E; Berdimuratova K; Mukanov K; Ramankulov Y
Antimicrob Resist Infect Control; 2017; 6():130. PubMed ID: 29299304
[TBL] [Abstract][Full Text] [Related]
40. Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Sirgel FA; Venter A; Heilmann HD
J Antimicrob Chemother; 1995 Feb; 35(2):349-51. PubMed ID: 7759400
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
